share_log

UBS Initiates Coverage On Bio-Rad Laboratories With Buy Rating, Announces Price Target of $395

UBS Initiates Coverage On Bio-Rad Laboratories With Buy Rating, Announces Price Target of $395

瑞银以买入评级启动对Bio-Rad实验室的报道,宣布目标股价为395美元
Benzinga ·  2023/12/07 06:10

UBS analyst Dan Leonard initiates coverage on Bio-Rad Laboratories (NYSE:BIO) with a Buy rating and announces Price Target of $395.

瑞银分析师丹·伦纳德以买入评级开始对Bio-Rad Laboratories(纽约证券交易所代码:BIO)进行报道,并宣布目标股价为395美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发